Nabumetone
Product Images NDC 45865-351

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Nabumetone (NDC 45865-351). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (351 60)

Nabumetone Tablets 750 mg label from Medsource Pharmaceuticals, package of 60 tablets. The label indicates the product is a generic for Relafen, beige oval tablets each weighing 1 gram. It includes warnings about dizziness, drowsiness, and alcohol use, with instructions in English and Spanish. Manufactured by Glenmark Generics Inc., USA, Mahwah, NJ.*

FDA Label Image

Emergency (Emergency)

A medication warning text panel listing serious side effects to watch for, including shortness of breath or trouble breathing, chest pain, weakness in one part or side of the body, slurred speech, and swelling of the face or throat.*

FDA Label Image

Metabolites (Metabolites)

A data table listing the percentages of various metabolites related to nabumetone, including unchanged nabumetone, 6-methoxy-2-naphthylacetic acid (6MNA), and other conjugated metabolites, with total percent dose values presented.*

FDA Label Image

Parent (Parent)

Chemical structure of 6-methoxy-2-naphthylacetic acid (6MNA), the active metabolite of Nabumetone. The diagram shows a naphthalene ring with a methoxy group and an acetic acid side chain attached.*

FDA Label Image

Provider (Provider)

A text panel listing potential symptoms or side effects, including nausea, fatigue, itching, jaundice, stomach pain, flu-like symptoms, vomiting blood, blood in bowel movements or black sticky stools, unusual weight gain, skin rash or blisters with fever, and swelling of the extremities.*

FDA Label Image

Rxnsaids (Rxnsaids)

A table listing nonsteroidal anti-inflammatory drugs (NSAIDs) with columns for generic names and their corresponding tradenames. The table includes drugs such as Celecoxib (Celebrex), Diclofenac (Cataflam, Voltaren, Arthrotec), Nabumetone (Relafen), Naproxen (Naprosyn, Anaprox, EC-Naproxyn), among others.*

FDA Label Image

Sideeffects (Sideeffects)

This image is a text panel listing serious and other side effects associated with the medication Nabumetone. Serious side effects listed include heart attack, stroke, high blood pressure, fluid retention, kidney failure, bleeding or ulcers, anemia, life-threatening skin and allergic reactions, liver failure, and asthma attacks. Other side effects include stomach pain, constipation, diarrhea, gas, heartburn, nausea, vomiting, and dizziness.*

FDA Label Image

Simcurves (Simcurves)

A line graph showing Nabumetone active metabolite (6MNA) plasma concentrations at steady state over 70 hours after once-daily dosing of 1000 mg (n=31) and 2000 mg (n=12). The chart displays concentration in mcg/mL on the vertical axis and time in hours on the horizontal axis, including variability bands of plus and minus two standard deviations for each dose group.*

FDA Label Image

Structure (Structure)

Chemical structure of nabumetone, showing a naphthalene ring with a methoxy group and a 4-(methyl ketone) side chain. The image includes the molecular formula C15H16O2 and molecular weight 228.3.*

FDA Label Image

Table1 (Table1)

A data table presenting pharmacokinetic parameters of Nabumetone in different groups: young adults receiving 1,000 mg and 2,000 mg doses, and elderly adults receiving 1,000 mg. The table includes Tmax (hours), half-life (t1/2 in hours), clearance (CLss/F in mL/min), and volume of distribution (Vdss/F in liters), each shown with mean values and standard deviations.*

FDA Label Image

Table2 (Table2)

A data table showing the number of patients with osteoarthritis (OA) and rheumatoid arthritis (RA) treated with varying doses of Nabumetone (500 mg to 2000 mg), alongside the mean or mode duration of treatment in years for each group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.